PHAT News & Events

Reports Q4 revenue $57.584M, consensus $57.44M. "We are pleased with our continued growth throughout 2025, leveraging the efficiency of our GI-focused strategy," said Steven Basta, President and Chief Executive Officer of Phathom. "Revenue increased significantly over the last three quarters. In the fourth quarter, we realigned our sales organization and enter 2026 with a stronger sales team and marketing initiatives designed to deepen engagement and increase prescribing for GERD across gastroenterologists."

For the full year 2026, Phathom is providing the following financial guidance: Net revenues of $320-$345 million, which includes approximately $17-$20 million; Gross- to-net of 55-59%; Gross margin of approximately 80%; Non-GAAP operating expenses, excluding stock-based compensation, of $235-$250 million; Operating profitability, excluding stock-based compensation, expected beginning in the third quarter 2026 and for the full year 2026